中国实验血液学杂志最新文献

{"title":"[The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].","authors":"Guo-Rong Wang, Guang-Zhong Yang, Yun Leng, Yin Wu, Ai-Jun Liu, Wen-Ming Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.021","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.021","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the effect of COVID-19 infection on the mobilization and collection of autologous peripheral blood stem cells in patients with multiple myeloma.</p><p><strong>Methods: </strong>The general baseline data, treatment factors before mobilization collection, collection status, and treatment overview after collection of autologous peripheral blood stem cells at Beijing Chaoyang Hospital affiliated with Capital Medical University from January 1, 2020 to July 15, 2023 were analyzed.</p><p><strong>Results: </strong>269 patients underwent mobilization and collection of autologous peripheral blood stem cells. Among them, 32 cases with COVID-19 infection history (COVID-19 group) and 237 cases without COVID-19 infection history (non-COVID-19 group). In the COVID-19 group, 17 cases were treated with chemotherapy (etoposide)+G-CSF, and 15 cases were treated with plerixafor +G-CSF. In the non-COVID-19 group, 214 cases were treated with chemotherapy +G-CSF, 17 cases were treated with plerixafor +G-CSF, and 6 cases were treated with chemotherapy + plerixafor +G-CSF. The number of CD34<sup>+</sup> cells, collection success rate, and excellence rate in the COVID-19 group and the non-COVID-19 group were ［5.52 (0.94-26.87) <i>vs</i> 4.80 (0.53-37.20)］×10<sup>6</sup>/kg (<i>P</i> =0.610), (93.8% <i>vs</i> 85.2%) (<i>P</i> =0.275), (62.5% <i>vs</i> 49.4%) (<i>P</i> =0.190), respectively. Among 113 patients mobilized with etoposide +G-CSF, the number of CD34<sup>+</sup> cells, success rate, and excellence rate collected from COVID-19 infection (17 cases) and non-COVID-19 infection (96 cases) were ［7.54 (2.66-26.87) <i>vs</i> 7.78 (2.26-37.20)］×10<sup>6</sup>/kg (<i>P</i> =0.847), (100.0% <i>vs</i> 100.0%) (no <i>P</i> value), (82.4% <i>vs</i> 86.5%) (<i>P</i> =0.655), respectively. Among 32 patients mobilized by plerixafor +G-CSF, the number of CD34<sup>+</sup> cells, success rate and excellence rate of COVID-19 infection (15 cases) and non-COVID-19 infection (17 cases) were ［3.82 (0.94-7.27) <i>vs</i> 4.11 (0.53-9.05)］×10<sup>6</sup>/kg (<i>P</i> =0.821), (86.7% <i>vs</i> 88.2%) (<i>P</i> =0.893), (40.0% <i>vs</i> 35.3%) (<i>P</i> =0.784), respectively. In 32 patients with COVID-19 infection, the number of CD34<sup>+</sup> cells collected by etoposide +G-CSF (17 cases) and plerixafor +G-CSF (15 cases), as well as the success rate and excellence rate were ［7.54 (2.66-26.87) <i>vs</i> 3.82(0.94-7.27)］×10<sup>6</sup>/kg (<i>P</i> =0.004), (100.0% <i>vs</i> 86.7%) (<i>P</i> =0.120), (82.4% <i>vs</i> 40.0%) (<i>P</i> =0.014), respectively. By 2023.7.31, 232 patients (86.2%, 232/269) had received transplantation, including 24 patients in the COVID-19 group and 208 patients in the non-COVID-19 group. The median number of CD34<sup>+</sup> cells infused in the two groups was ［3.67 (2.50-13.44) <i>vs</i> 3.11(1.12-19.89)］×10<sup>6</sup>/kg (<i>P</i> =0.058), the median days of neutrophil engraftment ［11(9-13) <i>vs</i> 11(9-17)］ (<i>P</i>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"455-462"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of the Influencing Factors of ABO Blood Group Antibody Origin and Titer in Neonates].","authors":"Meng-Jiao Yang, Li Zhang, Yu Zhou, Chun Yang, Xiang Shi","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.031","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.031","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the origin and influencing factors the titer of ABO blood group antibody in neonates.</p><p><strong>Methods: </strong>A total of 303 newborn blood samples collected in our hospital from August 2023 to March 2024 were selected for the detection of ABO blood group settings and the determination of the total titers of IgG and IgM blood group antibodies in plasma. IgM antibodies were treated with dithithreitol (DTT) to determine the titers of IgG antibodies. The total titer of the blood group antibody was compared with that of the IgG antibody. The clinical data of mothers and newborns were collected, and the correlation between the antibody titer and these clinical data was analyzed.</p><p><strong>Results: </strong>Among the 303 newborn specimens, 14 cases (4.62%) were identified to possess blood group antibodies. The influence of the maternal ABO blood group on the generation of high-potency blood group antibodies in newborns was observed to follow the order of O>B>A>AB, with a significant statistical difference ( <i>P</i> < 0.01). Of the 123 (40.59%) newborns born to mothers of type O, 121 (98.37%) had blood group antibody titers > 2. Of the 20 (6.60%) newborns born to mothers of type AB, all 20 (100.00%) had blood group antibody titers < 2. Among 89 (29.37%) mothers of type A and 71 (23.43%) mothers of type B, the titer of 100% newborn blood group antibody was less than 2, when the newborn blood group was incompatible with the mother's blood group; the titer of the newborn blood type antibody was higher or lower, when the newborn blood type was compatible with the mother's blood type. The titer of the newborn blood group antibodies is related to the number of pregnancies of the mothers and has no association with other clinical data (such as the mother's number of obortions), the number of production, fetal gestation age.</p><p><strong>Conclusion: </strong>The majority of ABO blood group antibodies in neonates are IgG antibodies from the mothers, and few are produced by the neonates themselves. In some neonates, IgG anti-A and/or anti-B can agglutinate with anti-stereotyped cells at room temperature. The maternal ABO blood type is the primary factor influencing the titer of the newborn blood type. The number of maternal pregnancies is a factor affecting the high titer ABO blood group antibodies in newborns.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"520-525"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Mechanism of Iron in Lymphocyte and Plasma Cell Diseases--Review].","authors":"Shu-Lin Luo, Fei-Fei Yang, Yan-Li Xu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.044","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.044","url":null,"abstract":"<p><p>As an important trace element, iron is involved in a variety of physiological processes. In recent years, studies have found that the occurrence and development of tumors are closely related to abnormal iron metabolism, and the mode of action is obviously heterogeneous. Tumor cells need more iron to promote their survival and proliferation, but iron overload can also have adverse effects on tumor cells, such as ferroptosis. Ferroptosis is a special regulatory mechanism of cell death, which is different from other regulated cell death pathways. It mainly induces cell death through excessive accumulation of iron-dependent lipid peroxide and reactive oxygen species (ROS). Recent studies have found that in the blood system, tumor cells of lymphoma and multiple myeloma (MM) are more sensitive to ferroptosis and affect disease progression through a variety of mechanisms. In this review, the mechanisms of ferroptosis in some subtypes of lymphoma and MM are described in detail, and the correlation between ferroptosis of hematological tumor cells and the occurrence and development of hematological tumors is revealed, aiming to provide new ideas for the treatment of these hematological diseases.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"601-605"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Significance of XPO1 High Expression in Diffuse Large B-Cell Lymphoma and Its Mechanism].","authors":"Jing Zhang, Yan Gu, Jia-Heng Guan, Xue Wu, Bao-An Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.013","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.013","url":null,"abstract":"<p><strong>Objective: </strong>To explore the expression and clinical significance of XPO1 in newly diagnosed adult diffuse large B-cell lymphoma (DLBCL), and further investigate its functional mechanism.</p><p><strong>Methods: </strong>Immunohistochemical testing was conducted for XPO1 expression in 93 cases of DLBCL and 30 cases of reactive lymphoid hyperplasia. A risk model was construed to find survival related genes in DLBCL patients. Cell proliferation, apoptosis, and cell cycle assays were performed to explore the effect of XPO1 inhibitor (KPT-8602) and <i>XPO1</i> knockdown. Differential expression gene (DEG) was examined based on the transcriptomes.</p><p><strong>Results: </strong>The expression of XPO1 in DLBCL patients was higher than that of the controls. Compared with XPO1 low-expression group, XPO1 high-expression group had a worse prognosis. The constructed risk model indicated that <i>XPO1</i> and 14 genes in nucleocytoplasmic transport pathway (NTP) might be potential prediction marker of adverse outcome in DLBCL. Moreover, KPT-8602 as well as the <i>XPO1</i> knockdown could inhibit cell proliferation, promote apoptosis, and induce cell cycle arrest in two DLBCL cell lines, Farage and SU-DHL-4. Based on the gene expression profiling in the datasets of DLBCL, patients were classified into <i>XPO1</i> high and <i>XPO1</i> low expression groups, and the <i>MYBL1</i> was identified as the down-stream effector of <i>XPO1</i>. Inhibiting the function of XPO1 or reducing its expression can significantly decrease the expression of <i>MYBL1</i> Conclusion: XPO1 is highly expressed in DLBCL, which is associated with poor prognosis. The oncogenic roles of the new <i>XPO1/MYBL1</i> signaling are identified in DLBCL and XPO1 inhibitor may be a potential option for newly-diagnosed DLBCL patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"393-406"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Effects of Pomalidomide-Based Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma].","authors":"Man Yang, Yan Huang, Ling-Xiu Zhang, Guo-Qing Lyu, Lu-Yao Zhu, Xian-Kai Liu, Yan Guo","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.017","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.017","url":null,"abstract":"<p><strong>Objective: </strong>To study the clinical effects of pomalidomide-based regimen in the treatment of relapsed and refractory multiple myeloma (RRMM).</p><p><strong>Methods: </strong>60 patients with RRMM in hematology department of the First Affiliated Hospital of Xinxiang Medical University from November 2020 to January 2023 were selected. Among them, 15 cases were treated with PDD regimen (pomalidomide + daratumumab + dexamethasone), and 45 cases were treated with PCD regimen (pomalidomide + cyclophosphamide + dexamethasone). The clinical effects were evaluated.</p><p><strong>Results: </strong>The median number of treatment cycles for the entire cohort was 5 (2-11), with an overall response rate (ORR) of 75.0%. The ORR of patients treated with PDD regimen was 73.3%, while the ORR of patients treated with PCD regimen was 75.6%. The ORR of 46 patients with non high-risk cytogenetic abnormalities (non-HRCA) was 86.9%, significantly higher than the 35.7% of 14 patients with HRCA (χ² =15.031, <i>P</i> < 0.05). The median PFS for all patients was 8.0(95%<i>CI</i> : 6.8-9.1) months and the median OS was 14.0 (95%<i>CI</i> : 11.3-16.7) months. Among patients treated with PDD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 7.0(95%<i>CI</i> : 4.6-9.3) months <i>vs</i> 4.0(95%<i>CI</i> : 3.1-4.8) months, χ² =5.120, <i>P</i> < 0.05; OS: not reached <i>vs</i> 6.0(95%<i>CI</i> : 1.1-10.9) months, χ² =9.870, <i>P</i> < 0.05]. Among patients treated with PCD regimen, the PFS and OS of patients with non-HRCA were significantly higher than those of patients with HRCA [PFS: 9.0(95%<i>CI</i> : 6.2-11.8) months <i>vs</i> 6.0(95%<i>CI</i> : 5.4-6.6) months, χ²=14.396, <i>P</i> < 0.05; OS: not reached <i>vs</i> 11.0(95%<i>CI</i> : 6.4-15.6) months, χ² =7.471, <i>P</i> < 0.05].</p><p><strong>Conclusion: </strong>The pomalidomide-based regimen has a good clinical effect and safety in the treatment of RRMM.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"431-436"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Identification of the Novel Allele <i>HLA-B</i>*54:01:11 Detected by NGS Using the Third Generation Sequencing Technology].","authors":"Nan-Ying Chen, Yi-Zheng He, Wen-Wen Pi, Qi Li, Li-Na Dong, Wei Zhang","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.038","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.038","url":null,"abstract":"<p><strong>Objective: </strong>To distinguish the ambiguous genotyping results of human leukocyte antigen (HLA), identify a novel <i>HLA-B</i> allele and analyze the nucleotide sequence.</p><p><strong>Methods: </strong>A total of 2 076 umbilical core blood samples from the Zhejiang Cord Blood Bank in 2022 were detected using the next generation sequencing technology (NGS) based on the Ion Torrent S5 platform. Among these a rare <i>HLA-B</i> allele with ambiguous combination result containing a base mutation was identified, and was further confimed by the third-generation sequencing (TGS) based on the nanopore technology.</p><p><strong>Results: </strong>The NGS typing result of <i>HLA-B</i> locus showed <i>HLA-B</i>* 46:18, 54:06 or <i>HLA-B</i>*46:01, 54:XX (including a base mutation), and nanopore sequencing confirmed the typing as <i>HLA-B</i>*46:01, 54:XX (including a base mutation). Compared with <i>HLA-B</i>*54:01:01:01, the <i>HLA-B</i>*54:XX allele showed one single nucleotide substitution at position 1014 T>C in exon 6, with no amino acid change. The nucleotide sequence of the novel <i>HLA-B</i>*54:XX has been submitted to the GenBank nucleotide sequence database and the accession number OP853532 was assigned.</p><p><strong>Conclusion: </strong>A ambiguous genotyping of the <i>HLA-B</i> Locus detected by NGS was distinguished by nanopore sequencing and a new <i>HLA-B</i> allele was successfully identified, which was officially named as <i>HLA-B</i>*54:01:11 by the World Health Organization Nomenclature Committee for Factors of the HLA System.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"565-568"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression and Function of miR-144 in β-Thalassemia].","authors":"Lan Yang, Ling Ling, Fan Yang, Lei Yang, Zhi-Chen Dai, Duo-Nan Yu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.027","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.027","url":null,"abstract":"<p><strong>Objective: </strong>To explore the expression and function of microRNA-144 (miR-144) in β-thalassemia (β-thal).</p><p><strong>Methods: </strong>The expression of miR-144 during the differentiation of murine erythroleukemia (MEL) cells and mouse embryonic liver-derived erythroid precursor cells was analyzed by real-time fluorescence quantitative PCR (qRT-PCR); The expression levels of miR-144 in peripheral blood and day-14.5 embryonic hepatocytes of wild-type (WT) and β-thal mice, as well as the expression levels of miR-144 in peripheral blood of β-thal patients, was also measured by qRT-PCR. The proportion of Ter119 and CD71 double positive cells in peripheral blood of mild and severe β-thal mice was analyzed by flow cytometry, and the expression levels of miR-144 in the peripheral blood of mild and severe β-thal mice and patients were compared; Bone marrow nucleated erythrocytes from WT mice and β-thal mice were sorted and the expression levels of miR-144 potential target genes were analyzed by gene chip.</p><p><strong>Results: </strong>The expression levels of miR-144 were gradually increased during the directed differentiation of mouse MEL cells and embryonic hepatocytes to the erythroid lineage (<i>r</i> _MEL=0.97, <i>r</i> _{embryonic hepatocytes}=0.86); Compared with WT mice, the expression levels of miR-144 in peripheral blood and 14.5-day embryonic hepatocytes of β-thal mice were significantly increased (<i>P</i> < 0.05); Compared with healthy controls, the patients with β-thal showed an increased expression levels of miR-144 in peripheral blood (<i>P</i> < 0.05). Compared with mice and humans with mild β-thal, the expression levels of miR-144 in peripheral blood of those with severe β-thal were significantly increased (<i>P</i> < 0.05). The expressions of potential target genes of miR-144 in nucleated erythroid cells of the β-thal mice were significantly reduced compared to the WT group.</p><p><strong>Conclusion: </strong>The expression level of miR-144 gradually increases in erythroid development, and compared with mild β-thal patients, the expression level of miR-144 in the peripheral blood is higher in severe β-thal patients. MiR-144 is expected to be an auxiliary diagnostic indicator for β-thal in clinical practice.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"491-497"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression and Clinical Significance of lncRNA <i>NCK1-AS1</i> in Acute Myeloid Leukemia].","authors":"Chen Cheng, Zi-Jun Xu, Pei-Hui Xia, Xiang-Mei Wen, Ji-Chun Ma, Yu Gu, Di Yu, Jun Qian, Jiang Lin","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.007","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.007","url":null,"abstract":"<p><strong>Objective: </strong>To detect and analyze the expression and clinical significance of long non-coding RNA tyrosine kinase non-catalytic region adaptor protein 1-antisense RNA1 (<i>NCK1-AS1</i>) in patients with acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>89 AML patients and 23 healthy controls were included from the People's Hospital Affiliated to Jiangsu University. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression levels of <i>NCK1-AS1</i> and <i>NCK1</i> in bone marrow samples. The relationship between the expression of <i>NCK1-AS1</i> and the clinical characteristics of patients were analyzed, as well as the correlation between <i>NCK1-AS1</i> and <i>NCK1</i>.</p><p><strong>Results: </strong>The expression level of <i>NCK1-AS1</i> in all AML, non-M3 AML and cytogenetically normal AML (CN-AML) patients was significantly higher than that in the control group (<i>P</i> < 0.01, <i>P</i> < 0.05, <i>P</i> < 0.01, respectively). In non-M3 AML, patients with high <i>NCK1-AS1</i> expression had a significantly lower hemoglobin level than those with low <i>NCK1-AS1</i> expression (<i>P</i> =0.036), furthermore, <i>NCK1-AS1</i> ^high patients had shorter overall survival than <i>NCK1-AS1</i>^low patients (<i>P</i> =0.0378). Multivariate analysis showed that <i>NCK1-AS1</i> expression was an independent adverse factor in patients with non-M3 AML ( <i>HR</i> =2.392, 95% <i>CI</i> :1.089-5.255, <i>P</i> =0.030). In addition, <i>NCK1</i> expression was also significantly upregulated in all AML, non-M3 AML and CN-AML patients compared with controls (<i>P</i> < 0.01, <i>P</i> < 0.01, <i>P</i> < 0.001, respectively). There was a certain correlation between <i>NCK1-AS1</i> and <i>NCK1</i> expression (<i>r</i> =0.37, <i>P</i> =0.0058).</p><p><strong>Conclusion: </strong>High expression of <i>NCK1-AS1</i> in AML indicates poor prognosis of AML patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"352-358"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Immunophenotypic Characteristics of Bone Marrow Granulocytes and Their Clinical Significance in Patients with Multiple Myeloma].","authors":"Ning-Fang Wang, Chong-Shan Zhao, Dong-Dong Zhang, Zhuo-Wen Cai, Fang-Fang Cai, Fang Liu, Peng-Hao Zhao","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.020","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.020","url":null,"abstract":"<p><strong>Objective: </strong>To explore the immunophenotypic characteristics of bone marrow granulocytes (G) and their clinical significance in patients with multiple myeloma (MM).</p><p><strong>Methods: </strong>The granulocyte immunophenotypes of bone marrow in 70 MM patients (MM group) and 40 anemia patients (control group) were detected by flow cytometry, and its correlation with clinical characteristics was further analyzed. Univariate and multivariate regression analysis were used to screen factors that affected prognosis.</p><p><strong>Results: </strong>The CD56⁺G%, CD13⁺G%, CD22⁺G% and CD117⁺G% in MM group were higher than those in the control group (all <i>P</i> <0.05). CD56⁺G% and CD117⁺G% in CR⁺VGPR group were significantly lower than those in PR+MR+PD group (both <i>P</i> <0.05). The CD10⁺G% in RISS Ⅲ stage and Ca²⁺ ≥2.65 mmol/L groups were increased (both <i>P</i> <0.05). The CD56⁺G% in elevated lactate dehydrogenase, β₂-microglobulin≥5.5 mg/L and hemoglobin <85 g/L groups were increased (all <i>P</i> <0.05), while the CD117⁺G% in high-risk cytogenetic positive group was decreased (<i>P</i> <0.05). The expression rate of CD molecules on granulocytes was divided into low (L) and high (H) groups according to the median value. The overall survival (OS) of the LCD56⁺G%, LCD13⁺G% and LCD22⁺G% groups was significantly prolonged (all <i>P</i> <0.05). CD13⁺G% and CD22⁺G% were independent risk factors for OS in MM patients (<i>HR</i>=0.443, 0.410, both <i>P</i> <0.05).</p><p><strong>Conclusion: </strong>The CD56⁺G%, CD10⁺G% and CD117⁺G% are closely correlated with clinical features in MM patients, while CD13⁺G% and CD22⁺G% are closely correlated with prognosis. Detection of CD molecules expression on granulocytes may be used to evaluate prognosis and guide treatment.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"447-454"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and Laboratory Characteristic Analysis of Patients with Newly Diagnosed Monoclonal Gammopathy Combined with Anemia].","authors":"Han Qian, Yue-Xia Wu, Min Yang, Yu-Ting Hu, Yu-Jie Kong, Qian Liu, Ying Xu","doi":"10.19746/j.cnki.issn.1009-2137.2025.02.042","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.02.042","url":null,"abstract":"<p><strong>Objective: </strong>To study the clinical and laboratory characteristics of monoclonal gammopathy anemia and explore the risk factors associated with anemia in monoclonal gammopathy.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 5 539 patients who underwent immunofixation electrophoresis at the First Affiliated Hospital of Chengdu Medical College from January 2016 to February 2024. A total of 351 newly diagnosed M protein positive patients were selected as the study subjects, including 270 in the anemia group and 81 in the non-anemia group. Laboratory test results were compared between the two groups, and logistic regression models were used to analyze the risk factors for anemia. ROC curve analysis was performed to evaluate the predictive value of risk factors for anemia in monoclonal gammopathy.</p><p><strong>Results: </strong>The proportion of non-anemic patients was 23.1% (81/351), with a median age of 67(60-75) years; the proportion of anemic patients was 76.9% (270/351), with a median age of 70(63-75) years. The total protein, globulin, urea, creatinine, uric acid, β₂-microglobulin, and ceruloplasmin levels in the anemia group were higher than those in the non-anemia group ( <i>P</i> < 0.05), while albumin, neutrophil count, lymphocyte count, monocyte count, complement C3, complement C4, haptoglobin, and transferrin levels were lower in the non-anemia group ( <i>P</i> < 0.05). After adjustment, multivariate logistic regression analysis shows that elevated GLB, increased β₂-MG, decreased ANC, and reduced complement C3 were independent risk factors for anemia in monoclonal gammopathy ( <i>P</i> < 0.05). ROC curve analysis demonstrates that GLB, β₂-MG, ANC, and complement C3 had good predictive value for anemia associated with monoclonal gammopathy.</p><p><strong>Conclusion: </strong>Elevated GLB, increased β₂-MG, decreased ANC, and reduced complement C3 are independent risk factors for anemia in monoclonal gammopathy (<i>P</i> < 0.05). The combined assessment of these four factors has good predictive value for anemia in monoclonal gammopathy.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 2","pages":"587-592"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}